ModernMedicine Resource Center More Topics
 

Biologic treatments for moderate-to-severe atopic dermatitis

Less itch and more sleep with baricitinibA phase two study of adults with moderate-to-severe atopic dermatitis shows that once-daily oral Janus kinase (JAK) 1 and 2 inhibitor baricitinib relieved itch and improved sleep, a study shows.
Gene identified as having a role in suppressing atopic dermatitisThe transcription factor "retinoid-related orphan receptor-alpha" (RORA) has been identified as a regulator of T regulatory (Treg) genes responsible for suppressing allergic skin inflammation, researchers report.
Methotrexate outperforms cyclosporine in atopic dermatitis studyThe duration of methotrexate administration proves to be longer than that of cyclosporine in atopic dermatitis, according to a small study that compared the two first-line immunosuppressive treatments for atopic dermatitis.
AAD meeting preview for atopic dermatitis treatmentsNew data and status updates for atopic dermatitis treatments in clinical trials will be presented at the American Academy of Dermatology annual meeting in San Diego this week. In this article, we offer some highlights.
Azathioprine and methotrexate safe and effective for atopic dermatitisA small study finds that the combination of methotrexate and azathioprine is safe and effective as maintenance treatment for patients with moderate-to-severe atopic dermatitis for up to five years.
Cornerstone therapy in atopic dermatitisMoisturizers were described as the “cornerstone of therapy” in atopic dermatitis in the 2014 AAD guidelines for topical therapies in atopic dermatitis, but the products differ greatly by ingredients which can improve the condition or make it worse.
Ocular comorbidities associated with atopic dermatitisOcular comorbidity risk is already high in patients with atopic dermatitis and may increase even further as biologic agents are introduced, a study shows.
Atopic dermatitis and psoriasis as a spectrum conditionThinking of psoriasis and atopic dermatitis as a spectrum, rather than separate diseases might lead to better understanding, and potentially better treatments.
Atopic Dermatitis in 2018Until recently, atopic dermatitis treatments were primarily limited to topical corticosteroids and systemic immunosuppressants. Now, two new therapies have reached clinical practice. Nineteen more are in development.
Dupilumab tames AD in difficult-to-treat patientsDupilumab given concomitantly with topical corticosteroids significantly improved signs and symptoms of atopic dermatitis (AD) in adults refractory to or intolerant of cyclosporine A, a study shows.